News

Calibration of schizophrenia treatment is a delicate balancing act

Publish date: February 23, 2016

 

EXPERT ANALYSIS AT THE NPA PSYCHOPHARMACOLOGY UPDATE

References

Dr. Weiden reported having numerous financial ties to the pharmaceutical industry, as well as being a stockholder of Delpor.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Positivity a core trait of successful aging
MDedge Family Medicine
Early treatment key in first-episode psychosis
MDedge Family Medicine
APA-IPS: Smartphone app found feasible for managing schizophrenia
MDedge Family Medicine
Patient-centered early intervention superior in first-episode psychosis
MDedge Family Medicine
VIDEO: Integrated care is key to ‘normal’ life with schizophrenia
MDedge Family Medicine
Medicaid scripts reveal rise in risky polypharmacy in children
MDedge Family Medicine
Burden of psychiatric comorbidity higher in MS patients
MDedge Family Medicine
Researchers highlight gaps in diabetes screening in patients on antipsychotics
MDedge Family Medicine
Stimulant use may raise psychosis risk for children of those with mental illness
MDedge Family Medicine
Antipsychotics may double to triple diabetes risk in youth
MDedge Family Medicine